Yong Yi

Yong Yi is a Principal Scientist at Iksuda Therapeutics since July 2022, specializing in the design and coordination of preclinical studies for antibody drug conjugates. Previously, Yong Yi served as a Senior Scientist, leading preclinical and translational activities, and collaborating with external vendors on study execution. Before joining Iksuda, Yong Yi worked as a Research Scientist at Orum Therapeutics, focusing on antibody neodegrader conjugates, and conducted extensive research on their mechanisms and therapeutic efficacy. Yong Yi's earlier experience includes a significant tenure at ImmunoGen, Inc., contributing to the development of multiple antibody-drug conjugates for various cancers, including key roles in IND submissions. Yong Yi began professional training as a Research Fellow at Massachusetts General Hospital, where research focused on the proteolytic products of huntingtin.